Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 613

1.

Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.

Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J.

Gynecol Oncol. 2007 Nov;107(2):266-73. Epub 2007 Aug 14.

PMID:
17698176
2.

[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].

Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ.

Ai Zheng. 2007 Mar;26(3):312-7. Chinese.

PMID:
17355798
3.

Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.

Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J.

Anticancer Res. 2006 Mar-Apr;26(2C):1683-9.

4.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H.

Br J Cancer. 1999 Apr;79(11-12):1746-51.

5.

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.

Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M.

Clin Cancer Res. 2001 Jun;7(6):1743-9.

6.

Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.

Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.

Thromb Res. 2007;120(5):753-62. Epub 2007 Jan 29.

PMID:
17258797
7.
8.

ErbB-3 predicts survival in ovarian cancer.

Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.

J Clin Oncol. 2006 Sep 10;24(26):4317-23. Epub 2006 Aug 8.

PMID:
16896008
9.

Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.

Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM.

Clin Cancer Res. 2001 Mar;7(3):551-7.

10.
11.

Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R.

Am J Surg Pathol. 2001 Dec;25(12):1493-500. Erratum in: Am J Surg Pathol 2002 Apr;26(4):539.

PMID:
11717538
12.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
13.
14.

Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.

Hazelbag S, Kenter GG, Gorter A, Fleuren GJ.

Int J Cancer. 2004 Dec 20;112(6):1020-8.

15.

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E.

Clin Cancer Res. 2001 Aug;7(8):2396-404.

16.

PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.

Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R.

Clin Cancer Res. 2003 Apr;9(4):1412-9.

17.
18.

Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.

Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T.

J Pathol. 1997 Dec;183(4):388-97.

PMID:
9496254
19.

Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.

Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I.

Lab Invest. 2003 Jun;83(6):861-70.

PMID:
12808121
20.

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.

Zhang W, Ling D, Tan J, Zhang J, Li L.

Oncol Rep. 2013 Feb;29(2):637-45. doi: 10.3892/or.2012.2148. Epub 2012 Nov 20.

PMID:
23174953

Supplemental Content

Support Center